CA Rachana Phadke Ranade - Standard Glass Lining | IPO Review | CA Rachana Ranade
Standard Glass Lining is one of India's top three manufacturers of glass-lined, stainless steel, and nickel alloy-based specialized engineering equipment, primarily serving the pharmaceutical and chemical industries. The company also ranks among the top suppliers of PTFE-lined pipelines and fittings. Its products, such as reactors and storage tanks, are crucial for preventing chemical reactions with metals during pharmaceutical manufacturing processes. The company generates 99% of its revenue domestically, with the pharmaceutical industry contributing over 80% of its sales. Financially, the company has shown impressive growth due to acquisitions, but recent growth has slowed. Risks include high customer concentration and increasing working capital days, which could lead to cash flow issues. The IPO aims to raise funds for capital expenditures and debt repayment. The industry is expected to grow, with the chemical and pharmaceutical sectors expanding at 9-12% and 8-10% respectively. However, the company's financial metrics, such as working capital days and customer concentration, pose potential risks.
Key Points:
- Standard Glass Lining is a leading manufacturer of specialized engineering equipment for the pharmaceutical and chemical industries in India.
- The company generates 99% of its revenue domestically, with significant contributions from the pharmaceutical sector.
- Recent financial growth was driven by acquisitions, but future growth may be slower due to high customer concentration and increasing working capital days.
- The IPO aims to fund capital expenditures and debt repayment, with a price band of 133 to 140 INR.
- Industry growth is expected at 9-12% for chemicals and 8-10% for pharmaceuticals, but financial risks remain due to customer concentration and cash flow management.
Details:
1. 📣 Welcome to the First IPO of 2025!
- Standard Glass Lining is one of the top three manufacturers of glass lined, stainless steel, and nickel alloy based specialized engineering equipment in India, ranked by revenue for fiscal 2025.
- The company is also among the top three suppliers of PTFE lined pipelines and fittings in India, again ranked by revenue for fiscal 2024.
- Their primary market includes the pharmaceutical and chemical industries, supplying essential equipment like reactors and storage tanks.
- Standard Glass Lining ensures that their reactors and storage tanks are lined with glass to prevent chemical reactions with metal, crucial for pharmaceutical processes like manufacturing APIs such as paracetamol.
- The company generates approximately 99% of its revenue from sales within India, with only 37% of sales related to exports.
2. 🏭 Understanding Standard Glass Lining's Business
- The pharmaceutical industry is the largest contributor, accounting for over 80% of revenue, indicating a strong dependency that could be a risk if market conditions change.
- Chemicals contribute 12.5% to the revenue, while other industries account for 5.61%, showing limited diversification.
- Revenue from reaction systems has decreased from 68% to 56%, potentially due to market saturation or competitive pressures.
- Conversely, storage systems revenue increased to 30%, suggesting a strategic shift or growing demand in storage solutions.
- Plant engineering and services have seen significant growth, rising from 5% to 133%, indicating a successful expansion in service offerings.
3. 🌟 Market Growth and Industry Analysis
3.1. Chemical Industry Growth
3.2. Healthcare and Pharmaceutical Market
3.3. Glass-lined Equipment Market
3.4. India's Role in the Global Pharma Industry
4. 📈 Financial Performance and Key Acquisitions
- Revenue from operations grew from 2,400 million to over 5,400 million from fiscal year 22 to 24.
- IIDA revenue increased from over 400 million to 1,000 million in the same period.
- PAT (Profit After Tax) grew from 251 million to almost 600 million.
- The company experienced a CAGR of 50% to 55% in these metrics, indicating a rapid growth phase.
- Significant growth was observed between fiscal year 22 to 23, with revenue nearly doubling from 2,400 million to almost 5,000 million.
- From fiscal year 23 to 24, growth was less pronounced, with revenue increasing from almost 5,000 to 5,400 million, and PAT from 534 to 600 million, indicating about a 10% growth.
- Two acquisitions in the second half of fiscal 22 - S2 Engineering Services and Stand Pumps Engineering Industries - significantly contributed to the spike in revenue and profitability.
- The impressive numbers in fiscal 22 to 23 were largely driven by these acquisitions, which added their revenues and profits to the company's financials.
5. ⚠️ Addressing Risks and Challenges
5.1. Revenue Concentration Risks
5.2. Contractual and Supplier Risks
5.3. Cash Flow Management Challenges
5.4. Litigation and Financial Risks
6. 🔍 Valuation Insights and Peer Comparison
- The company's P/E ratio is 39.7704, which is lower than the industry average, suggesting a potentially undervalued stock compared to peers.
- To enhance understanding, additional metrics such as EV/EBITDA and Price/Sales should be considered to provide a comprehensive view of the company's relative valuation.
- A lower P/E ratio can indicate either a bargain opportunity or market skepticism about future growth, necessitating further analysis of company fundamentals.
- Comparing these metrics with direct competitors can highlight strengths or weaknesses in market positioning and investor perception.
7. 🔔 IPO Details and Competitor Performance
7.1. Market Valuation
7.2. Revenue Comparison
7.3. Earnings Per Share (EPS)
8. 🤔 Informed Investment Decisions and Conclusion
- The IPO opens on January 6th, 2025, with a price band of 133 to 140. Out of the total 410 CR issue, 210 CR is a fresh issue, and the remaining 200 CR is an offer for sale.
- GMM Foder listed and initially rose impressively but has been moving sideways since 2020, remaining at almost the 2020 level.
- H Glascoat rose almost 300% post-listing but is currently around its IPO level.
- Investors should not jump into investments based on high GMP alone; instead, they must consider fundamental aspects like industry analysis, valuation, and risks before making informed decisions.